Pomegranate juice has therapeutic effect observed through in vitro and in vivo studies. It can be used as antiviral, antibacterial, antidiabetic and anticarcinogenic material. This work includes in vitro studies for modified pomegranate as anticancer for liver and breast cancer. N-aminorhodanine is reacted with p-chlorobenzaldehyde to form 2-(4-chlorobenzylideneamino)-5-thioxoisothiazolidin-3-one (CBAT). CBAT was characterized with FTIR and 1HNMR. Pomegranate juice is then modified with CBAT. CBAT is reacted with phenolic –OH groups of pomegranate juice to make modification. The modified pomegranate was characterized using FTIR and 1HNMR spectroscopy. It was examined against both human hepatoma HepG2 cells and breast cancer cells MCF7 through in vitro studies. It was found that modified pomegranate has good synergistic inhibitory and pro apoptotic effects on human hepatoma HepG2 cells and breast cancer cell MCF7. Modified pomegranate has stronger effect on HepG2 cells than on MCF7 cells.